Our MG community took note of the recent news regarding the latest therapy options that aim to reduce the burden of hours-long treatment delivery with IVIG. For those who are responding well to this new treatment, it’s a game changer. But we recognize that many patients are interesting in learning more, so here are some questions that have come in from the MG community with answers provided by Dr. Betty Soliven of the University of Chicago School of Medicine and a member of our Medical Advisory Board. [Click here to read more.]
Conquer MG is seeking nominations for qualified individuals to serve on its Board of Trustees.
This is an incredible group of people who care deeply about the well-being of those who experience or know someone with myasthenia gravis. Our role as board members is to help people with myasthenia gravis and their caregivers access information, resources, and community as a way of empowering them to take charge of their disease and how it uniquely impacts their lives.
Email your completed application to Michelle Weber, firstname.lastname@example.org.
From our partner, argenx is a new podcast, the “Untold Stories: Life with Myasthenia Gravis.” Take a listen to the first season that explores the real and untold stories of life with myasthenia gravis (MG), finding hope and community in each MG journey.
UCB Announces U.S. FDA Approval of RYSTIGGO[®] (rozanolixizumab-noli) for the Treatment of Adults with Generalized Myasthenia Gravis
What you need to know:
- This is a new therapy that is designed as a monoclonal antibody that binds to the neonatal Fc receptor (FcRN).
- The delivery of this therapy is subcutaneous injection – so it’s quicker and more convenient than infusion therapies that take hours.
- Rystiggo is approved to treat the most common type of MG (AChR-antibody) and also approved to treat MuSK-antibody (muscle-specific kinase) myasthenia – which is typically more severe and hasn’t responded as well to treatment.
For more information, talk to your health care provider.
Read the full press release [here].